Sanford (SAN) has announced a solid result for FY22 and provided updates on its key strategic initiatives, but no FY23 guidance was included in this result; the outlook includes key positives from strong price and demand, as well as the commissioning of the Bioactives plant and a net benefit from a weaker NZD